Thiotepa Drug Asset Due Diligence Report 2026

This Thiotepa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

287

Registered trials

194

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Thiotepa can convert its Small molecule drug profile and DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Thiotepa (query alias: thiotepa)
Modality / target	Small molecule drug; DNA; DNA inhibitors, DNA alkylating agents
Highest global status	Approved
Originator	Wyeth Holdings LLC
Active developers	Jiangsu Hengrui Pharmaceuticals Co., Ltd., Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd., Sumitomo Pharma Co., Ltd.

The MCP disease footprint includes Lymphoma, Childhood Malignant Solid Neoplasm, Beta-Thalassemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07677813	Phase 2	Not yet recruiting	66	2year PFS
NCT07616154	Phase 2	Not yet recruiting	45	GVHD-free and rejection free survival (GRFS)
NCT07604987	Phase 2	Recruiting	33	Overall response rate (ORR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Phase 2; n=84; evaluation: not stated. Reported fields: -; -; No chronic GVHD = 17 Participants

EFFICACY AND SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF PEDIATRIC ATYPICAL TERATOID/RHABDOID TUMOR: A RETROSPECTIVE STUDY

Not Applicable; n=4; evaluation: Positive. Reported fields: DFS = 3.0 Pts

EFFICACY AND SAFETY OF TOTAL BODY IRRADIATION COMBINED WITH THIOTEPA VERSUS TOTAL BODY IRRADIATION IN ALLO-HSCT FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA

Not Applicable; n=102; evaluation: Positive. Reported fields: DFS(1-year) = 44.1 % ; DFS(1-year) = 48.2 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Thiotepa addresses Lymphoma, Childhood Malignant Solid Neoplasm, Beta-Thalassemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-05-12	CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China	Phase 2	US$20.0M stated total
2019-11-18	Accord partners with ADIENNE to market Tepadina for hematological diseases and solid tumors in Europe and India.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “DNA alkylating agent for treating cancer and tumor patients with negative p53 gene mutation or defect”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO